Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Read the Original
This page is a summary of: Reply to Aitken et al., “Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?”, Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals, DOI: 10.1128/aac.01163-17.
You can read the full text:
The following have contributed to this page